Selected novel fusion proteins derived from hepatitis B virus (HBV) splice variants and their proposed role and/or effect on HBV replication
Splice variant | Novel protein | Size (kDa) | Proposed role/effect on HBV replication | References |
---|---|---|---|---|
Sp1 | HBSP | 10 |
| [75, 79, 80] |
| [81] | |||
| [5] | |||
| [82] | |||
| [83–85] | |||
| [86] | |||
p21.5 | 21.5 |
| [88] | |
C-terminal truncated core protein | 21 |
| [87] | |
| [1] | |||
N-terminal truncated pol protein | 39 |
| [48] | |
Sp3 | Precore-pol | 48 |
| [9, 89] |
Core-pol | 47 |
| [9, 89] | |
Sp7 | HBDSP | 15 |
| [76] |
Sp9 | Precore-surface | 45 |
| [89] |
Core-surface | 44 |
| [89] | |
C-terminal truncated pol with new open reading frame | 12 |
| [89] | |
N-terminal truncated pol | 50 |
| [89] | |
Sp10 | Core-surface | 35 |
| [78] |
Sp13 | Pol-surface | 43 |
| [90] |
| [77] | |||
| [77] |
HBSP: hepatitis B spliced protein; pol: polymerase; HBDSP: hepatitis B doubly spliced protein; HBsAg: hepatitis B surface antigen
LCM: Investigation, Writing—original draft, Writing—review & editing. ML: Writing—review & editing, Supervision. PAR: Conceptualization, Writing—review & editing, Supervision.
PAR has received investigator-initiated industry-funded grants from Gilead. None of this support is relevant to the work in this manuscript. The remaining authors declare no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
LCM, ML and PAR were funded by National Health and Medical Research Council (NHMRC) grant [1145977]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2024.